Epicutaneous immunization converts subsequent and established antigen‐specific T helper type 1 (Th1) to Th2‐type responses
Epicutaneous immunization converts subsequent and established antigen‐specific T helper type 1 (Th1) to Th2‐type responses
复制标题
表皮免疫将随后建立的抗原特异性 T 辅助细胞 1 型 (Th1) 反应转化为 Th2 型反应
DOI：
10.1111/j.1365-2567.2006.02401.x
复制
发表时间：
2006
期刊：
影响因子：
6.4
通讯作者：
S. Strobel
中科院分区：
文献类型：
--
作者：
J. Strid;R. Callard;S. Strobel
表皮免疫是一种潜在的局部疫苗递送新技术。它靶向免疫丰富的皮肤环境，同时具有非侵入性免疫程序的优势。通过破坏表皮的角质层，可以通过激活常驻朗格汉斯细胞来实现天然佐剂作用。这否定了共同应用有毒佐剂的正常需要。在屏障破坏的皮肤上进行表皮免疫可诱导强效抗原特异性全身免疫，并具有强烈的辅助性T细胞2型（Th 2）偏倚。我们在这里表明，表皮免疫增强了随后T细胞对相同抗原的反应活力。诱导的全身性Th 2应答防止通过注射在完全弗氏佐剂（CFA）中的抗原诱导的Th 1应答的发展。先前的表皮免疫导致抗原特异性干扰素-γ和免疫球蛋白G2 a（IgG 2a）的产生减少，并增强对CFA免疫的白细胞介素-4，IgG 1和IgE应答。此外，表皮免疫将已建立的Th 1应答转化为Th 2应答，如干扰素-γ和IgG 2a的特异性减少以及白细胞介素-4和IgE的增强所证明的。表皮免疫的Th 2优势可能作为Th 1优势疾病（例如自身免疫性类风湿性关节炎、1型糖尿病、桥本甲状腺炎和多发性硬化症）的免疫调节程序具有直接的治疗应用。
Epicutaneous immunization is a potential novel technique for topical vaccine delivery. It targets the immunologically rich milieu of the skin while having the advantage of being a non‐invasive immunization procedure. By disrupting the stratum corneum of the epidermis a natural adjuvant effect can be achieved through activation of resident Langerhans cells. This negates the normal need for co‐application of noxious adjuvants. Epicutaneous immunization on barrier‐disrupted skin induces potent antigen‐specific systemic immunity with a strong T helper type 2 (Th2) bias. We show here that epicutaneous immunization enhances the vigour of a subsequent T‐cell response to the same antigen. The induced systemic Th2 response prevents the development of Th1 responses induced through injection of antigen in complete Freund's adjuvant (CFA). Prior epicutaneous immunization results in reduced production of antigen‐specific interferon‐γ and immunoglobulin G2a (IgG2a) and enhanced interleukin‐4, IgG1 and IgE responses to immunization with CFA. Moreover, epicutaneous immunization converts an established Th1 response to a Th2 response, as demonstrated by the specific reduction of interferon‐γ and IgG2a and the enhancement of interleukin‐4 and IgE. This Th2 dominance of epicutaneous immunization may have direct therapeutic application as an immune‐modulating procedure in Th1‐dominant diseases such as autoimmune rheumatoid arthritis, type 1 diabetes, Hashimoto's thyroiditis and multiple sclerosis.